Just caught CRL's Q4 earnings and there's some interesting mixed signals here. The stock actually fell on the news despite beating both earnings and revenue expectations, which is pretty typical when the market was already pricing in the good numbers. CRL reported adjusted EPS of $2.39, beating estimates by 2.51%, and revenues came in at $994.2 million, also beating the consensus. Full-year 2025 EPS hit $10.28, so the company actually delivered solid results across the board.

What caught my attention though is the margin expansion - gross margins jumped 368 basis points year-over-year and operating margins expanded 347 bps to 22%. That's the kind of operational improvement investors usually like to see. But here's the thing: organic revenue actually declined across all three segments, which suggests the growth is coming more from cost management than top-line momentum. CRL's guidance for 2026 is pretty cautious too - they're only expecting flat to 1.5% growth, which is basically saying they don't see a strong rebound coming anytime soon.

The company does have decent liquidity with $213.8 million in cash and positive operating cash flow, so there's financial stability there. Management seems optimistic about demand stabilization in the biotech space, but the stock's reaction tells you the market isn't convinced yet. CRL carries a Zacks Rank #3 (Hold) for a reason - it's a solid company with improving margins, but the organic growth headwinds are real.